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Abstract
Objective To investigate whether screening kidney transplant recipients
aged over 50 years for colorectal cancer with a faecal immunochemical
test for haemoglobin might be justified, by determining the prevalence
of advanced colorectal neoplasia and evaluating the diagnostic accuracy
of faecal haemoglobin testing compared with colonoscopy in a population
of kidney transplant recipients at otherwise average risk.
Design Cross sectional prevalence and diagnostic accuracy study with
index test of faecal haemoglobin and reference standard of colonoscopy.
SettingOutpatient clinics in metropolitan and regional hospitals in South
Australia.
Participants 229 kidney transplant recipients aged 50 years and over,
who were at least 6 months (mean 9.0 (SD 8.4) years) post-transplant
and otherwise at average risk of colorectal cancer, completed the study
between June 2008 and October 2011.
Interventions Faecal immunochemical testing (Enterix Insure) for human
haemoglobin, followed by colonoscopy with histological evaluation of
retrieved samples.
Main outcomemeasures Prevalence of advanced colorectal neoplasia,
defined as an adenoma at least 10 mm in diameter, villous features,
high grade dysplasia, or colorectal cancer; sensitivity, specificity, and
predictive values of faecal haemoglobin testing for advanced neoplasia
compared with colonoscopy.
Results Advanced colorectal neoplasia was found in 29 (13%, 95%
confidence interval 9% to 18%) participants, including 2% (n=4) with
high grade dysplasia and 2% (n=5) with colorectal cancer. Faecal testing
for haemoglobin was positive in 12% (n=28); sensitivity, specificity, and
positive and negative predictive values for advanced neoplasia were
31.0% (15.3% to 50.8%), 90.5% (85.6% to 94.2%), 32.1% (15.9% to
52.4%), and 90.1% (85.1% to 93.8%). Colonoscopy was well tolerated,
with no significant adverse outcomes. To identify one case of advanced
neoplasia, 8 (6 to 12) colonoscopies were needed.
Conclusions Kidney transplant recipients aged over 50 years have a
high prevalence of advanced colorectal neoplasia. Faecal haemoglobin
screening for colorectal neoplasia has similar performance characteristics
in transplant recipients to those reported in general population studies,
with poor sensitivity but reasonable specificity. Surveillance colonoscopy
might be a more appropriate approach in this population.
Trial registration Australian New Zealand Clinical Trials Registry
ACTRN12608000154303.
Correspondence to: P T Coates toby.coates@health.sa.gov.au
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Kidney transplantation is the preferred treatment for end stage
kidney disease. Short and medium term outcomes for transplant
recipients are excellent,1 but mortality is significant in the long
term, in large part due to malignancy.2 Transplant recipients
need long term immunosuppressive treatment to prevent graft
loss, and this has been associated with an increased risk of
cancer.3 4Although the greatest relative increase in risk has been
seen for non-melanoma skin cancers and cancers associated
with viral infection,3 the risk of more common solid organ
cancers, including colorectal cancer, is also significantly
increased with a relative risk compared with the general
population of between two and three.3-5 Transplant recipients
who develop colorectal cancer are often younger at diagnosis
and have poorer outcomes when compared with the general
population.5-9
Colorectal cancer is the third most commonly diagnosed cancer
worldwide10; major risk factors include age, male sex, and a
family history, and survival is strongly linked to the stage of
cancer at diagnosis.11 In the general population, screening with
guaiac based faecal occult blood tests followed by colonoscopy
in people with a positive test has been shown to reduce the
mortality of colorectal cancer.12 Faecal occult blood screening
is recommended in people over the age of 50 with average
risk.13-16 Immunochemical tests specific for faecal human
haemoglobin have largely replaced the guaiac based tests used
in early trials, on the basis of improved acceptability and
performance.17 18 The effectiveness of screening depends on the
identification and removal of colorectal adenomatous polyps
with features associated with an increased risk of malignant
transformation and early stage malignant disease, together
termed “advanced colorectal neoplasia.”19Colonoscopy can also
been used to screen patients at average risk,20-23 but this is
associated with higher costs, less convenience, and the potential
for adverse outcomes in a small number of patients.24 It is,
however, accepted as the most appropriate screening test for
patients at moderate to high risk of colorectal cancer.13-15 25
No studies have been published on the benefits or harms of
screening kidney transplant recipients for colorectal cancer.
Clinical practice guidelines for the care of kidney transplant
recipients have suggested screening from the age of 50 years
with faecal haemoglobin and that this might be cost effective.26-28
However, the prevalence of advanced colorectal neoplasia is
unknown, as is the diagnostic accuracy of faecal haemoglobin
testing in kidney transplant recipients. Importantly, faecal
haemoglobin might be less specific for colorectal neoplasia
owing to the incidence of positive tests from colitis due to
cytomegalovirus infection or toxicity of immunosuppressive
drugs, for example.26 In addition, no data have been published
on the safety of colonoscopy in transplant recipients, which
might have increased harms due to the negative influence of
immunosuppression.26
To fill this gap in available data, we did a cross sectional study
of prevalence and diagnostic accuracy in a kidney transplant
recipient population, using both faecal haemoglobin testing and
colonoscopy to determine the prevalence and characteristics of
advanced colorectal neoplasia and to evaluate the diagnostic
accuracy of a faecal immunochemical test for human
haemoglobin (the index test) compared with colonoscopy (the
reference standard) to detect advanced colorectal neoplasia in
this population.
Methods
Study design, setting, and participants
This was a population based, cross sectional study of prevalent
kidney transplant recipients, conducted through outpatient clinics
at metropolitan and regional hospitals in the state of South
Australia. Three tertiary renal services, which collectively care
for all adult transplant recipients in the state, were involved.
The study took place between June 2008 and October 2011.
Kidney transplant recipients were eligible if they were aged
over 50 years, were at least six months post-transplant, and gave
written informed consent. Patients were invited to participate
during the course of routine follow-up in the outpatient clinic.
Exclusion criteria were previous colorectal cancer or adenoma
with high grade dysplasia, colonoscopy within 12 months,
symptoms or signs suggestive of colorectal cancer or other
significant non-neoplastic colorectal disease, known or suspected
familial colorectal cancer syndrome (patients with cancer in one
close relative were eligible), chronic inflammatory bowel
disease, unstable cardiopulmonary disease, bleeding disorder
or unacceptable risk of bleeding, terminal illness or life
threatening malignancy, or a failed transplant and subsequent
return to dialysis.
Patients with a history of previous rectal bleeding attributed to
haemorrhoids or other non-neoplastic disease were eligible
provided bleeding was not an active problem. Patients receiving
anticoagulant treatment were also eligible provided they could
discontinue this treatment at the time of screening colonoscopy,
if requested by the endoscopist. Patients who had had a previous
faecal haemoglobin test, colonoscopy, or both were eligible
provided they did not meet any of the other exclusion criteria.
Study procedures
Study participants completed a faecal immunochemical test for
human haemoglobin by using the Enterix Insure kit (Enterix
Australia). This test uses a brush to obtain each faecal sample,
which is then applied to a testing card; two samples are taken
from consecutive bowel motions. Participants completed a
questionnaire concerning timing of the samples, colorectal
symptoms, and details of colorectal disease, previous screening,
and family history. A history of anticoagulant or antiplatelet
drug use and allergies was also sought. We reviewed medical
records to provide additional data.
De-identified test cards were forwarded to a central laboratory
(Enterix Australia, Sydney) for processing using methods
previously described.18 Study investigators had no involvement
in the laboratory analysis of samples.
After faecal testing, and regardless of the result, participants
were referred for colonoscopy. To reduce the risk of dropout,
participants were informed of faecal haemoglobin results before
colonoscopy only on request. Interventional gastroenterologists
and colorectal surgeons did colonoscopies; to meet ethical
clearance requirements, we could not blind physicians to the
faecal haemoglobin result. In the three major participating
centres, specific colonoscopy lists were arranged for this study;
colonoscopies were also done in regional hospitals and in the
private sector.
Participants received bowel preparation according to the
endoscopist’s preference—usually a polyethylene glycol based
preparation alone or in combination with a sodium picosulfate
based preparation. Sodium phosphate preparations were not
used. At physicians’ discretion, participants could be admitted
for intravenous hydration before colonoscopy. Participants had
a serum creatinine measurement to estimate renal function
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(glomerular filtration rate) before and after colonoscopy.29 Any
adverse events were noted.
During colonoscopy, the location and size of all polypoid lesions
were recorded, and the presence of any other lesions was noted.
We defined location within the colon as either proximal
(caecum, ascending or transverse colon), distal (descending or
sigmoid colon), or in the rectum. Biopsy forceps were used to
estimate the size of each polyp. If the examination of the bowel
was incomplete because of failure to reach the caecum or poor
bowel preparation, the patient was asked to return for a second
attempt at the discretion of the endoscopist; we included
combined results in the analysis when this occurred within six
months of the date of the original colonoscopy. If a participant
had surgery as a result of colonoscopy findings, we included
results from surgically resected specimens in the analysis.
Classification of index test and reference
standard results
We recorded faecal immunochemical test results as either
positive or negative for the presence of human haemoglobin,
as reported by the laboratory. Retrieved colorectal biopsy
samples were sent to local laboratories for histological
examination. Pathologists were not aware of the faecal
haemoglobin result or that patients were enrolled in this study.
The final diagnosis for each participant was determined on the
basis of combined results of colonoscopy and histology of
retrieved or resected specimens.
To calculate the prevalence of advanced colorectal neoplasia,
as well as other pathology, we classified participants on the
basis of their most advanced lesion. For example, we classified
a participant with an adenoma with high grade dysplastic
changes and a tubular adenoma as having an advanced adenoma
with high grade dysplasia. We defined advanced colorectal
neoplasia, in accordance with previous studies,20-22 as the
presence of either cancer or an advanced adenoma—a tubular
adenoma of at least 10 mm diameter, a villous or tubulovillous
adenoma (that is, at least 25% villous), or an adenoma with high
grade dysplasia. We diagnosed and staged cancer according to
the American Joint Committee on Cancer’s classification.30
Data analysis
We used Stata software version 11.2 for all statistical analyses.
We express data as raw values and percentages for categorical
data and as mean (standard deviation) or median (interquartile
range) for continuous data. We used Student’s t test to compare
continuous variables and logistic regression to determine
associations between categorical variables. We set statistical
significance for hypothesis testing at 0.05 (that is P≤0.05). All
statistical tests were two tailed.
To evaluate the diagnostic accuracy of faecal haemoglobin to
detect advanced colorectal neoplasia, we compared results with
colonoscopy findings by using two by two tables.We calculated
sensitivity, specificity, positive and negative predictive values,
likelihood ratios, and diagnostic odds ratios. We present
estimates with 95% confidence intervals.
Sample size
We estimated the prevalence of advanced colorectal neoplasia
in transplant recipients to be 12%, on the basis of a general
population prevalence of approximately 6%23 and transplant
registry data suggesting an increased risk of colorectal cancer
in transplant recipients of at least twofold. We estimated that a
sample size of 218 participants would allow us to detect a
prevalence (proportion) of advanced neoplasia of 12% (0.12),
with a resulting binomial exact 95% confidence interval that
ranged from 7.9% to 17.0% (that is, less than 5% in either
direction). Assuming a completion rate of 60-70%, we sought
to target between 310 and 360 patients for recruitment.
Results
Participants
From information available from hospital units’ records, we
estimated that the population of eligible transplant recipients in
South Australia would be approximately 400 patients. Between
1 June 2008 and 30 June 2011, 360 patients were assessed for
initial eligibility and invited to participate. The figure⇓ shows
the flow of patients through the study, along with the primary
outcome of advanced colorectal neoplasia. Patients who were
excluded (and reasons for this) or who withdrew from the study
are noted. In total, 229 patients completed the study, a
completion rate of 64%; table 1⇓ outlines the characteristics of
these participants. Twenty-six (10%) patients who completed
faecal haemoglobin testing did not have colonoscopy and were
excluded from analysis. Table 2⇓ shows details of previous
colorectal history and screening. Outcomes for all participants
were finalised according to available results as at 31 October
2011.
Quality of faecal haemoglobin testing and
colonoscopy
Faecal testing cards were developed a mean of 9.0 (SD 4.4)
days after the first faecal sample was taken and 8.2 (4.1) days
after the second sample. The median interval between the faecal
haemoglobin result and completion of colonoscopy was 82
(interquartile range 47-135) days.
The caecum was intubated in 219 (96%) of 229 screening
colonoscopies. Colonoscopy was incomplete in six cases;
screening was supplemented with computed tomographic
colonography (n=2), barium enema (n=2), or a repeat
colonoscopy 12 months later (n=1). One participant did not
attend the appointment for computed tomographic colonography.
In four cases, no data on caecal intubation was recorded in the
colonoscopy report.
Views of the bowel were considered at least partly reduced
because of suboptimal preparation in 36 (16%) participants.
Seven (3%) participants returned for a follow-up colonoscopy
with improved preparation and had composite results from both
procedures included in study outcomes.
Primary outcomes
Table 3⇓ shows the final diagnoses after colonoscopy, classified
according to the most advanced lesion. Overall, 29 (13%, 95%
confidence interval 9% to 18%) participants had advanced
colorectal neoplasia; 4 (2%) participants had a high grade
dysplastic lesion, and 5 (2%) had previously undiagnosed
colorectal cancer. The appendix gives further details of the
location and staging of the cancer and the surgical procedure
performed. In addition to the participants who had surgery for
cancer, one participant with a large adenoma had a right
hemicolectomy.
Faecal haemoglobin was positive in 28 (12%, 8% to 17%)
participants.We found no association between a previous history
of visible rectal bleeding or the use of aspirin, warfarin, or
clopidogrel and the faecal haemoglobin result (P>0.05). Tables
4⇓ and 5⇓ show analyses of the diagnostic accuracy of faecal
haemoglobin to detect advanced colorectal neoplasia. Among
the five participants ultimately diagnosed as having cancer,
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e4657 doi: 10.1136/bmj.e4657 (Published 25 July 2012) Page 3 of 14
RESEARCH
three had positive faecal haemoglobin (sensitivity of 60%); the
tumour’s location was not associated with the faecal
haemoglobin result (P>0.05).
Of the 72 participants with neoplasia, 18 (8%) had two or more
adenomas and seven (3%) had three or more. One participant
with colorectal cancer also had a tubulovillous adenoma. In
addition to colorectal neoplasia, non-neoplastic disease was
frequently detected; the most common diagnoses were
diverticular disease (n=76; 33%) and haemorrhoids (n=23; 10%).
The appendix gives further details of the location of lesions and
of non-neoplastic disease.
Safety of colonoscopy and adverse events
No significant adverse events occurred as a result of
colonoscopy. Four (2%) patients had minor bleeding in
association with polypectomy that was controlled
endoscopically. Other minor adverse events are noted in the
appendix.
Renal function results were available before and after
colonoscopy for 226 participants (three had data missing). Mean
estimated glomerular filtration rate did not change (55.1 (SD
19.3) versus 54.5 (19.4) mL/min/1.73 m2; P>0.05, paired t test).
Twenty-one (9%) participants were admitted to hospital for
intravenous hydration (mean creatinine 171.0 (80.6) μmol/L)
before colonoscopy. No adverse outcomes were noted in this
group.
Sensitivity and subgroup analyses
We did a sensitivity analysis to determine if the diagnostic
accuracy of faecal haemoglobin testing would be significantly
affected by verification bias due to the exclusion of 26 patients
who did not have colonoscopy. To estimate the effect of missing
reference standard data, we assumed hypothetical best case and
worst case scenarios from the perspective of faecal testing and
added the results to the observed data: best case—positive =
advanced neoplasia present, negative = prevalence of advanced
neoplasia same as observed data for negative faecal haemoglobin
results (10%); worst case—positive = no advanced neoplasia,
negative = double prevalence advanced neoplasia (20%). Under
these scenarios, sensitivity reduced slightly (range 26.5-30.3%);
specificity was largely unchanged (91.0-91.4%).
To take account of “suboptimal” colonoscopy (that is, caecum
not intubated or poor preparation, without a follow-up
procedure) or a long interval between faecal sampling and
colonoscopy (>6 months), we estimated diagnostic accuracy
separately with these participants excluded. Faecal haemoglobin
performed slightly better with optimal colonoscopy (n=188
participants), with an increase in sensitivity (36.0%, 18.0% to
57.5%), specificity (92.0%, 86.7% to 95.7%), and the diagnostic
odds ratio (6.49, 2.46 to 17.3). No improvement occurred when
we excluded longer time intervals (n=196; diagnostic odds ratio
3.71, 1.5 to 9.24).
Predictors of colorectal neoplasia
In univariate logistic regression analyses, the only characteristic
of participants that was significantly associated with an increased
risk of cancer was age (unadjusted odds ratio 1.16 (95%
confidence interval 1.01 to 1.33) per year). We found similar
results when we analysed age in 5 year bands (odds ratio 2.07
(1.04 to 4.13) for every 5 years above 55). All patients diagnosed
as having cancer were male; none had had previous screening
colonoscopy or a family history of cancer. No identifiable
characteristics of patients were significantly associated with
advanced neoplasia.
Previous screening for colorectal cancer
Seventy-eight (34%) participants had had one or more
colonoscopies before enrolment in this study (table 2⇓). A family
history of colorectal cancer (odds ratio 2.37, 1.10 to 5.10) and
a history of rectal bleeding (2.00, 1.09 to 3.68) were both
associated with a previous colonoscopy. We did not find any
significant differences in the rates of advanced and
non-advanced neoplasia between participants who had had
previous screening in a post hoc analysis (data not shown).
Discussion
In a population of asymptomatic kidney transplant recipients
aged over 50 years at otherwise average risk for colorectal
cancer, we found a high prevalence of advanced colorectal
neoplasia (13%, 95% confidence interval 9% to 18%). To detect
one case of advanced colorectal neoplasia, 8 (6 to 12)
participants needed to have colonoscopy. Faecal haemoglobin
had poor sensitivity (31.0%, 15.3% to 50.8%) but reasonable
specificity (90.5%, 85.6% to 94.2%) for advanced neoplasia. If
colonoscopy had been done only after a positive faecal
haemoglobin test (as in population screening), three participants
would have needed to have colonoscopy for each case identified,
but 20 (69%) cases of advanced neoplasia would have gone
undetected.
This is the first study to evaluate faecal haemoglobin screening
for colorectal neoplasia in kidney transplant recipients, and it
is the only study of colonoscopy surveillance among transplant
recipients of a similar age and risk profile to the general
population included in trials of screening that showed reduced
mortality from colorectal cancer. This study presents for the
first time prospective data on the safety of routine surveillance
colonoscopy in kidney transplant recipients and shows that this
can be implemented without adverse effects in a population
with a wide range of renal function and comorbidity.
Strengths and limitations of study
This study has several important strengths. We recruited a high
proportion of potentially eligible transplant recipients in South
Australia, reaching the target sample size in just over three years.
Of 360 patients whowere identified, 71% enrolled and submitted
a faecal sample, and 64% completed the study—a high rate for
a study involving an intervention such as colonoscopy, reducing
the potential for selection bias. Quality of performance of
colonoscopy was high (96% caecal intubation rate); the
diagnostic accuracy of faecal haemoglobin was not significantly
affected when suboptimal colonoscopies were excluded. A
sensitivity analysis indicated that the 10% of participants
excluded because of not having a colonoscopy would not have
introduced a significant risk of verification bias.
Because we included a broad range of patients, from both
metropolitan and regional settings (not just those cared for at
the transplanting centre), who had colonoscopies done in a
variety of setting by a variety of operators, these results are
more likely to be generalisable to other transplant populations,
although the high participation rate achieved could be argued
to reflect a cohort of patients that is more compliant and
cooperative thanmight be found in other jurisdictions. However,
the demographic and comorbidity profiles of the participants
in this study are similar to those of the transplant population
aged over 50 years in Australia as a whole and those reported
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in international comparisons.1 2 31We chose an age of eligibility
of 50 years on the basis that current guidelines recommend
starting screening from this age onwards.13 14 16 Although
evidence shows that the relative risk of colorectal cancer is
highest in younger transplant patients,5 the absolute risk in those
aged under 50 remains low. Sex, family history, and a history
of rectal bleeding due to non-neoplastic disease were not
discriminating factors, and screening was offered from six
months after transplantation, although the median time
post-transplant was 6.5 years.
A potential criticism of our study is that we used a cross
sectional design without a control (that is, non-transplant
recipient) group, which limits our ability to directly compare
the findings with the general population. However, this study
was designed to fill the gaps in evidence for screening of
transplant recipients, rather than as a comparison with the
general population. Doing a large scale colonoscopy study in a
comparable general population cohort truly at average risk would
have been ethically and logistically difficult, given established
screening guidelines and that a population screening programme
has been implemented in Australia, similar to those in other
countries.14 32 33 Such a study of participants at average risk
selected from the general population by using electoral (voter)
registrations encountered difficulties in recruiting participants
to have colonoscopy and produced limited results.34
This study has limited statistical power to identify predictors
of risk of neoplasia or to compare subgroups owing to the
relatively small number of cases of advanced colorectal
neoplasia and cancer. Larger studies in multiple jurisdictions
would be needed to identify sufficient cases to investigate the
relations between factors such as immunosuppressive drugs or
other transplant related factors and colorectal neoplasia.
Although laboratory analysis of faecal samples and the
interpretation of histology were done in a blinded fashion, we
were not able to blind endoscopists to the faecal haemoglobin
result. This was because of ethical requirements to ensure that
abnormal test results were made available. This may have
introduced “expectation” bias through greater effort being made
to identify neoplastic disease at colonoscopy after a positive
result and might potentially have increased the specificity of
faecal haemoglobin. However, in clinical practice this
information would always be available to a physician doing
colonoscopy.
In our study, we included participants who had had a previous
colonoscopy, as long as it wasmore than a year before enrolment
in the study. This creates a potential for “conservative” bias and
implies that the prevalence of neoplasia in a population of
participants naive to screeningmight be higher than our findings
suggest. However, we judged it inappropriate to exclude such
participants on the basis that little has been known about the
development or progression of pre-malignant colorectal
neoplasia in transplant recipients, whereas the poorer outcomes
from cancers in this group have been reported for some time.6 7 9
None of the cancers identified in this study was found in a
pre-screened patient, although no differences existed in the rates
of advanced and non-advanced adenomas between previously
screened and screen naive participants.
Comparisons with other studies
In a meta-analysis of studies of screening with colonoscopy in
the general population, with a similar age, sex, and family
history profile to this study, the prevalence of colorectal cancer
was 0.78% (0.13% to 2.97%) and that of advanced neoplasia
was 5.0% (4.0% to 6.0%).23 The finding of a prevalence estimate
of advanced colorectal neoplasia (the precursor to colorectal
cancer) in this study of 13% (that is, approximately twice the
prevalence in the general population) is consistent with other
studies showing a standardised incidence ratio of colorectal
cancer of approximately two to three in transplant recipients.3-5
The increased risk of many types of cancers in transplant
recipients has been associated with immunosuppression3;
however, we were not able to show an association between the
duration or type of immunosuppression and neoplasia, perhaps
because of the relatively small number of cases. Other as yet
unrecognised factors may also have contributed to the increased
risk of colorectal cancer in these patients, and larger studies of
transplant populations will be needed to determine these.
In line with current clinical practice, we chose a faecal
immunochemical test (Insure, Enterix Australia) as a means to
screen for colorectal neoplasia. The sensitivity and predictive
value of this test were poor for advanced colorectal neoplasia,
although specificity was better. Although several stools were
sampled, testing was done on a one-off basis, and sensitivity
could potentially be improved with serial testing.12 35 The Insure
faecal immunochemical test has been found to have superior
diagnostic accuracy for the detection of advanced colorectal
neoplasia compared with sensitive guaiac faecal occult blood
tests (such as Hemoccult II SENSA),18 and it can speed detection
of interval cancers when used in a colonoscopy surveillance
programme.35 In addition, it had the highest level of acceptability
to patients in a randomised trial of participation in screening
that included several different immunochemical tests,36 and it
had a high screening uptake rate and acceptability to patients
in the large Australian bowel cancer screening pilot.37
The performance characteristics of immunochemical faecal
haemoglobin tests to identify advanced colorectal neoplasia
have been variable across a range of studies.38-41 However, a
large study of a one-off faecal haemoglobin versus colonoscopy
found a sensitivity and specificity for advanced neoplasia of
27.1% and 95.1%,40 comparable to our findings. Faecal
haemoglobin thus seems to have similar diagnostic accuracy to
detect advanced colorectal neoplasia in both the transplant and
general populations. Factors such as sub-clinical colitis from
cytomegalovirus infection or drug toxicity, or potentially
microscopic haematuria, which might be present in some
transplant recipients, most commonly in the early post-transplant
period, do not seem to have resulted in any significant adverse
effect on specificity in this predominantly long term
post-transplant cohort.
In a case-control study of colonoscopy surveillance done as
“usual care” in 315 kidney transplant recipients compared with
630 general population controls referred for screening
colonoscopy (and therefore unlikely to be truly at “average risk”
owing to referral bias), Park and colleagues reported prevalences
of 7.0% for advanced adenomas and 1.9% for cancers.42 The
odds ratios were 3.5 for advanced adenomas and 12.0 for cancers
in screened transplant recipients. However, most of the
transplant cohort were aged under 50, and such a population
would be expected to have low rates of advanced colorectal
neoplasia, compared with the older population included in our
study.
Conclusions, policy implications, and
questions for future research
The findings of this study have important implications for the
development of guidelines on screening for colorectal cancer
in kidney transplant recipients. Although the sensitivity of the
immunochemical faecal haemoglobin test is poor, its
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performance as a screening test for neoplasia in transplant
recipients is comparable to that reported in studies of population
screening, without any apparent loss of specificity. Colonoscopy
seems to be safe to use as a surveillance tool in transplant
recipients.
Given the difficulties and costs of doing studies of this type in
transplant recipient populations, or indeed randomised
interventional trials, definitive data to determine whether the
benefits of screening outweigh the harms are unlikely to be
available. Our study provides novel data that can be used in
decision analyses and cost effectiveness studies to inform
clinical practice guidelines, which to date have relied on
extrapolations of general population data.26 28 In addition, long
term follow-up of this cohort compared with an unscreened
transplant population should provide comparative data on the
outcomes of screening transplant recipients for colorectal cancer.
From a payer’s perspective, a simplistic analysis of our data
would suggest that the estimated cost of detecting one advanced
neoplasia through surveillance colonoscopy of transplant
recipients, at an estimated cost of $A1192 (£786; €990; $1219)
per procedure,43 would be $A9536 (95% confidence interval
$A7152 to $A14 304), but the cost effectiveness of such an
approach is unknown. How transplant patients might regard
surveillance colonoscopy is unclear, but the high participation
rate here suggests that many are comfortable with this approach.
In conclusion, the main findings of this study are that a high
prevalence of advanced colorectal neoplasia exists in kidney
transplant recipients over the age of 50 and that, compared with
when it is used in the general population, faecal haemoglobin
screening of transplant recipients has similarly low sensitivity
although acceptable specificity for neoplasia. Given the high
prevalence of neoplasia, screening with faecal haemoglobin
testing alone will miss significant lesions with the potential to
develop into colorectal cancer. Taken together with previously
reported increased risk of colorectal cancer and poor outcomes,
these findings lead us to conclude that surveillance with
colonoscopy may be the most appropriate approach to reduce
the risk of colorectal cancer in kidney transplant recipients.
Further studies are needed to assess the outcomes and costs of
such an approach.
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Tables
Table 1| Characteristics of study participants who completed screening. Values are numbers (percentages) unless stated otherwise
Value (n=229)Characteristic













122.2 (47.3)Mean (SD) serum creatinine (µmol/L)
55.1 (19.3)Mean (SD) MDRD eGFR (mL/min/1.73 m2)
Cause of end stage kidney disease:
127 (55)Glomerulonephritis






29 (13)Second or subsequent transplant
Immunosuppressive drugs at time of screening:
24 (10)Triple—ciclosporin based (+ MMF/azathioprine and steroids)
53 (23)Triple—tacrolimus based (+ MMF/azathioprine and steroids)
45 (20)Triple—mTOR inhibitor based (+ MMF/azathioprine and steroids)
35 (15)Dual—ciclosporin based (+ MMF/azathioprine)
12 (5)Dual—tacrolimus based (+ MMF/azathioprine)
10 (4)Dual—mTOR inhibitor (+ MMF/azathioprine)
25 (11)Dual—MMF/azathioprine + steroids
21 (9)Other (including steroid or MMF alone, experimental agents)
1 (<1)Not on immunosuppression at time of screening
1 (<1)Not recorded
86 (38)Current or former smoker
History of other significant medical conditions:
93 (41)Cardiovascular disease
81 (35)Diabetes
23 (10)Chronic lung disease
Previous malignancy:
75 (33)Non-melanoma skin cancer (SCC or BCC)
20 (9)Other*
Antiplatelet or anticoagulant drug use:
69 (30)Aspirin
8 (3)Clopidogrel
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe





BCC=basal cell carcinoma; MDRD eGFR=glomerular filtration rate estimated using four variable modification of diet in renal disease equation; MMF=mycophenolic
acid derivative (mycophenolate mofetil or mycophenolic acid sodium); mTOR inhibitor=mammalian target of rapamycin inhibitor (sirolimus or everolimus);
SCC=squamous cell carcinoma.
*Melanoma (n=4); prostate (n=4); bladder (n=3); cervical (n=2); head and neck (n=2); renal (n=2); endometrium (n=1); breast (n=1); lymphoma (n=1); leukaemia
(n=1).
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Table 2| Reported colorectal history and previous screening of study participants
No (%) (n=229)Reported participants’ history item
24 (10)Family history of colorectal cancer in first degree relative*
History of non-neoplastic colorectal disease (not polyps):
14 (6)Any non-neoplastic disease
11 (5)Diverticulosis
3 (1)Other
History of colonic polyps:
17 (7)Any polyps
8 (3)Previous low grade tubular adenomas
9 (4)Polyps—details unknown or unspecified
History of rectal bleeding before study:
57 (25)Any rectal bleeding
35 (15)Haemorrhoids
22 (10)Other non-neoplastic causes (anal fissure, diverticulitis, other)
Rectal bleeding reported initially at time of faecal sample submission:
1 (<1)Within 4 weeks of sampling
0At time of faecal sampling
Previous faecal screening for human haemoglobin/occult blood:
79 (34)Any
9 (4)Known positive result in past
78 (34)Previous colonoscopy (screening or otherwise) at any time
Previous colonoscopy after transplant:
38 (17)At any time after transplant
21 (9)Within 1-5 years of screening study
17 (7)>5 years before screening study
Previous colonoscopy before transplant:
40 (17)At any time before transplant
19 (8)Within 1-5 years of screening study
21 (9)>5 years before screening study
*More than one affected first degree relative was an exclusion criterion; no participants reported this.
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Table 3| Final diagnosis in study participants, according to most advanced lesion
No (%) (n=229)Diagnosis
157 (69)Normal or non-neoplastic disease
43 (19)Non-advanced adenoma
24 (10)Advanced adenoma:
11 (5)Tubular adenoma ≥10 mm
9 (4)Villous/tubulovillous adenoma (regardless of size)
4 (2)High grade dysplasia (regardless of size)
5 (2)Colorectal cancer
29 (13, 95% CI 9 to 18)Prevalence of advanced colorectal neoplasia
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Table 5| Diagnostic accuracy estimates of faecal haemoglobin screening for detection of advanced colorectal neoplasia
Point estimate (95% CI)Parameter
31.0 (15.3 to 50.8)Sensitivity (%)
90.5 (85.6 to 94.2)Specificity (%)
32.1 (15.9 to 52.4)Positive predictive value (%)
90.1 (85.1 to 93.8)Negative predictive value (%)
3.27 (1.64 to 6.52)Positive likelihood ratio
0.762 (0.595 to 0.977)Negative likelihood ratio
4.29 (1.75 to 10.60)Diagnostic odds ratio
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e4657 doi: 10.1136/bmj.e4657 (Published 25 July 2012) Page 13 of 14
RESEARCH
Figure
Fig 1 Flow of participants through study
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e4657 doi: 10.1136/bmj.e4657 (Published 25 July 2012) Page 14 of 14
RESEARCH
